The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions

Ann Intern Med.: August 2014

Background: Chronic hepatitis C virus (HCV) infection causes a substantial health and economic burden in the United States. With the availability of direct-acting antiviral agents, recently approved therapies and those under development, and 1-time birth-cohort screening, the burden of this disease is expected to decrease.

Objective: To predict the effect of new therapies and screening on chronic HCV infection and associated disease outcomes.

Design: Individual-level state-transition model.

Setting: Existing and anticipated therapies and screening for HCV infection in the United States.

Patients: Total HCV-infected population in the United States.

Measurements: The number of cases of chronic HCV infection and outcomes of advanced-stage HCV infection. Read More